For human epidermal growth factor receptor 2 (HER2)-positive patients, the recommended first-line treatment option for advanced cancers is the combination of the anti-HER2 antibody trastuzumab with chemotherapy (4, 5). The gene discussed is ERBB2; the disease is cancer.